ANIX
vs
S&P 500
ANIX
S&P 500
Over the past 12 months, ANIX has underperformed S&P 500, delivering a return of -7% compared to the S&P 500's +12% growth.
Stocks Performance
ANIX vs S&P 500
Performance Gap
ANIX vs S&P 500
Performance By Year
ANIX vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Anixa Biosciences Inc
Glance View
Anixa Biosciences, Inc. is a biotechnology company, which engages in developing therapies and vaccines that are focused on critical unmet needs in oncology and infectious disease. The company is headquartered in San Jose, California and currently employs 4 full-time employees. The firm is developing therapies and vaccines that are focused on oncology and infectious disease. The firm is developing chimeric endocrine receptor T-cell technology, a chimeric antigen receptor T-cell (CAR-T) technology focused on treating ovarian cancer, and anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein functions of the virus. The company is also developing vaccine against triple negative breast cancer (TNBC), the lethal form of breast cancer, and a vaccine against ovarian cancer. Its CAR-T technology can be used as a treatment against multiple solid tumor types. The Company’s segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics, Cancer Diagnostics activities, and Patent Licensing activities. Its subsidiary Certainty Therapeutics, Inc. (Certainty), is developing immuno-therapy drugs against cancer.
